The AIM-HN and SEQ-HN Study: A 2 Cohort Non-comparative Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

Brief description of study

The purpose of this research study is to see how effective the study drug is to treat your tumor. Other reasons for conducting the study are: • To determine for how long the study drug may reduce the size or slow down the growth of your tumor. • To determine the side effects of the study drug. • To study your tumor and determine why it responds or not to treatment with this study drug.


Clinical Study Identifier: s18-00146
ClinicalTrials.gov Identifier: NCT03719690
Principal Investigator: Zujun Li
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.